218 related articles for article (PubMed ID: 33557783)
1. One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Keogh RJ; Aslam R; Hennessy MA; Coyne Z; Hennessy BT; Breathnach OS; Grogan L; Morris PG
BMC Cancer; 2021 Feb; 21(1):140. PubMed ID: 33557783
[TBL] [Abstract][Full Text] [Related]
2. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Shaw EG; Wang M; Coons SW; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
J Clin Oncol; 2012 Sep; 30(25):3065-70. PubMed ID: 22851558
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
5. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Prabhu RS; Won M; Shaw EG; Hu C; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
J Clin Oncol; 2014 Feb; 32(6):535-41. PubMed ID: 24419119
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Bouffet E; Mornex F; Jouvet A; Thiesse P; Mertens P; Helfre S; Sindou M; Bret P
Bull Cancer; 1997 Oct; 84(10):951-6. PubMed ID: 9435796
[TBL] [Abstract][Full Text] [Related]
7. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Jakacki RI; Jamison C; Mathews VP; Heilman DK; Dropcho E; Cornetta K; Macdonald DR; Williams DA
Med Pediatr Oncol; 1998 Dec; 31(6):483-90. PubMed ID: 9835900
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
10. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Cai Y; Jiang YG; Wang M; Jiang ZH; Tan ZG
Medicine (Baltimore); 2020 Sep; 99(38):e22238. PubMed ID: 32957367
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
[TBL] [Abstract][Full Text] [Related]
13. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Levin VA
Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
[No Abstract] [Full Text] [Related]
14. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
17. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
van den Bent MJ
Neuro Oncol; 2014 Dec; 16(12):1570-4. PubMed ID: 25355680
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
Medical Research Council Brain Tumor Working Party
J Clin Oncol; 2001 Jan; 19(2):509-18. PubMed ID: 11208845
[TBL] [Abstract][Full Text] [Related]
19. Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Mazzocco P; Honnorat J; Ducray F; Ribba B
Comput Math Methods Med; 2015; 2015():297903. PubMed ID: 26788118
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Qian Y; Maruyama S; Kim H; Pollom EL; Kumar KA; Chin AL; Harris JP; Chang DT; Pitt A; Bendavid E; Owens DK; Durkee BY; Soltys SG
Neuro Oncol; 2017 Nov; 19(12):1651-1660. PubMed ID: 28666368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
